A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...

Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

While TB and meningitis are rare among patients receiving systemic psoriasis therapies, IL-17 inhibitors increase the risk for candidiasis.

Psoriasis is often called a skin condition, which is a bit like calling a house fire a smoke problem. It is an immune disease ...

While dermatologists prescribe coal tar shampoos for specific scalp conditions, it’s important to understand when and how ...

Dr. Bunick introduces the panel's second case: a 72-year-old retired school administrator with plaque psoriasis diagnosed at ...

Arcutis Biotherapeutics, Inc. announced data presented across its ZORYVE® (roflumilast) portfolio as well as real-world research on the long-term use of topical corticosteroids at the 35thEuropean ...

If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.

Multi-country discrete-choice experiment presented at the Fall Clinical Dermatology Conference demonstrates that skin ...

Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEAD a  study evaluating ICOTYDE ®  (icotrokinra), the first and only targeted oral peptide that precisely ...

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment ...

A new NHANES-based study of 11,668 US adults finds that a higher red blood cell distribution width-to-albumin ratio is ...